Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    LB 100

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lixte Starts Study On LB-100 For Pre-Cancerous Cell Removal
    Lixte Starts Study On LB-100 For Pre-Cancerous Cell Removal

    31 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/31/3052287/0/en/LIXTE-Launches-New-Study-to-Determine-if-Certain-Pre-Cancerous-Cells-Found-in-an-Aging-Population-Can-Be-Eliminated-by-LB-100.html

    GLOBENEWSWIRE
    31 Mar 2025
    Share Share
    LIXTE Biotechnology Updates Progress on LB-100 for Cancer
    LIXTE Biotechnology Updates Progress on LB-100 for Cancer

    27 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/27/3050542/0/en/LIXTE-Biotechnology-Provides-Update-On-Progress-with-Proprietary-Compound-LB-100-to-Treat-Ovarian-and-Colorectal-Cancer.html

    GLOBENEWSWIRE
    27 Mar 2025
    Share Share
    LIXTE's LB-100 Increases Colon Cancer Cell Recognition By Immune System
    LIXTE's LB-100 Increases Colon Cancer Cell Recognition By Immune System

    06 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/06/2894649/0/en/Scientific-Journal-Reports-Findings-that-Show-LIXTE-s-Lead-Clinical-Compound-LB-100-Increases-Recognition-of-Colon-Cancer-Cells-by-the-Immune-System.html

    GLOBENEWSWIRE
    06 Jun 2024
    Share Share